Half Year 2025 Medartis Holding AG Earnings Call Transcript
Key Points
- Medartis Holding AG (XSWX:MED) reported an impressive organic revenue growth of 15.3% for the first half of the year, exceeding expectations.
- The integration of NeoOrtho is on track, with structural changes planned to consolidate teams and facilities in Brazil.
- The company has successfully completed the acquisition of KeriMedical, with plans to launch in the US market, supported by FDA readiness.
- Medartis has raised its guidance for the second half of the year to a 14% to 16% growth, reflecting a positive trend in sales.
- The company maintains a strong cash position with CHF121 million, ensuring financial flexibility for future investments and acquisitions.
- The US tariffs of 39% are expected to have a significant impact, with a high single-digit million impact anticipated for 2026.
- The gross margin slightly decreased due to FX impacts and the inclusion of KeriMedical as a distributor, which initially diluted margins.
- The Latin America region, excluding NeoOrtho, showed underperformance, with growth not meeting expectations.
- The company faces challenges in the Japanese market, particularly in the upper extremity business, which requires attention.
- The impact of FX resulted in more than CHF5.2 million in unrealized non-cash losses, affecting the net income.
Good morning and welcome to Medartis' half-year results conference.
Thank you for joining us today on a busy day. We will be referencing the presentation slides published this morning on our website. I would equally encourage you to review our comprehensive half-year report, which contains the complete financial statements, as well as additional details on recent business combinations. I'm pleased to introduce Matthias Schupp, our CEO, who is presenting, for the second time, results, and is the first time on his own guidance; and Dirk Kirsten, who is familiar to most of you from previous calls.
Before we begin, please note two important points. First, as always, we would like to draw your attention to the disclaimer, which you see on slide 2 here, especially for forward-looking statements. And then we would also encourage you to submit questions. You can do -- either do that in writing via the Q&A field that should be available to everyone on the desktop, the ones who are using Android, but not the ones who use mobile iPhone
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
